Cipher Pharmaceuticals (PHE) Price & Analysis
PHE Stock Chart & Stats
- Day’s Range
- EUR 8.10 - EUR 8.10
- 52-Week Range
- EUR 7.00 - EUR 12.20
- Previous Close
- EUR 8.20
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 211.80M
- Enterprise Value
- EUR 420.80M
- Total Cash (Recent Filing)
- EUR 9.10M
- Total Debt (Recent Filing)
- EUR 366.40K
- Price to Earnings (P/E)
- 8.2
- Beta
- 0.12
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- 0.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
High Margins And Operating Efficiency
Exceptionally high gross and EBITDA margins provide resilience against product volatility. The 6% YTD EBITDA increase, despite lower revenue, indicates that cost control and operating efficiency can protect profitability over the next several quarters.
Debt-Free Balance Sheet And Cash Generation
A debt-free balance sheet and positive operating cash flow give Cipher flexibility to fund commercialization, withstand product-specific setbacks, and pursue acquisitions or licensing without immediate dependence on equity issuance or expensive borrowing.
Epuris Market Share And Reimbursement Expansion
Epuris combines established Canadian leadership with growing volume and a potential reimbursement expansion. Broader public-plan access could enlarge the addressable patient base, improve prescribing economics, and support durable share gains.
Bears Say
Natroba U.S. Revenue Pressure
Natroba is facing a structural channel challenge rather than a one-day disruption. Reduced Medicaid volumes pressure the company’s U.S. revenue base, while new direct-to-patient and retail channels will require execution and time to offset the decline.
Declining Top-Line And Licensing Revenue
Revenue contraction across both direct product sales and licensing indicates that growth is not yet broad-based. Lower partner shipments also expose earnings to commercialization timing and partner demand, making future top-line recovery less predictable.
Uncertain Business-Development Pipeline
Cipher’s acquisition and licensing model depends on replenishing and expanding its product portfolio. Uncertain deal timing, combined with the abandoned opportunity, could delay diversification and leave results more dependent on the existing Natroba and Epuris base.
Cipher Pharmaceuticals News
PHE FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
What is Cipher Pharmaceuticals’s market cap?
When is Cipher Pharmaceuticals’s upcoming earnings report date?
How were Cipher Pharmaceuticals’s earnings last quarter?
Is Cipher Pharmaceuticals overvalued?
Does Cipher Pharmaceuticals pay dividends?
What is Cipher Pharmaceuticals’s EPS estimate?
How many shares outstanding does Cipher Pharmaceuticals have?
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Cipher Pharmaceuticals Stock Smart Score
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Craig J. Mull
- Employees
- 5
- Website
- www.cipherpharma.com
- Address
- 5750 Explorer Drive, Mississauga, ON, L4W 0A9, CA
Cipher Pharmaceuticals (PHE) Earnings & Revenues
PHE Earnings Call
Earnings Call SentimentPositive
The call conveyed a cautiously positive outlook: while the U.S. business (Natroba) experienced clear top-line pressure—driving a 10% decline in quarter revenue and a 19% decline in Natroba sales versus prior year—the company offset those headwinds with strong margin performance, SG&A reductions, cash generation, year-to-date EBITDA growth (+6% YTD), and concrete commercial and reimbursement progress for Epuris (14% revenue growth, expanded pCPA LOI and 47.1% market share). Management laid out actionable mitigation plans for U.S. channel diversification (DTC, retail, delivery), maintained an opportunistic M&A/in-licensing posture, and preserved liquidity and financing optionality. Overall, positives (sustained high margins, Epuris momentum, cost efficiencies, solid cash and financing capacity) meaningfully outweigh the operational revenue setbacks in the quarter.
View all DE:PHE earnings summariesPHE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |